home / stock / ortx / ortx quote
Last: | $16.70 |
---|---|
Change Percent: | 0.3% |
Open: | $16.65 |
Close: | $16.70 |
High: | $16.72 |
Low: | $16.63 |
Volume: | 372,349 |
Last Trade Date Time: | 01/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.7 | $16.65 | $16.7 | $16.72 | $16.63 | 372,349 | 01-23-2024 |
$16.65 | $16.6 | $16.65 | $16.65 | $16.585 | 60,671 | 01-22-2024 |
$16.61 | $16.51 | $16.61 | $16.63 | $16.51 | 89,454 | 01-19-2024 |
$16.57 | $16.54 | $16.57 | $16.6 | $16.5 | 204,700 | 01-18-2024 |
$16.55 | $16.39 | $16.55 | $16.55 | $16.39 | 247,663 | 01-17-2024 |
$16.44 | $16.41 | $16.44 | $16.45 | $16.4 | 392,742 | 01-16-2024 |
$16.44 | $16.4 | $16.44 | $16.445 | $16.4 | 31,853 | 01-15-2024 |
$16.44 | $16.4 | $16.44 | $16.445 | $16.4 | 31,853 | 01-12-2024 |
$16.4 | $16.41 | $16.4 | $16.45 | $16.4 | 233,867 | 01-11-2024 |
$16.42 | $16.4 | $16.42 | $16.43 | $16.4 | 92,401 | 01-10-2024 |
$16.4 | $16.4 | $16.4 | $16.425 | $16.385 | 146,693 | 01-09-2024 |
$16.4 | $16.41 | $16.4 | $16.41 | $16.39 | 48,773 | 01-08-2024 |
$16.4 | $16.4 | $16.4 | $16.44 | $16.395 | 89,085 | 01-05-2024 |
$16.41 | $16.44 | $16.41 | $16.45 | $16.39 | 133,951 | 01-04-2024 |
$16.41 | $16.42 | $16.41 | $16.43 | $16.38 | 139,877 | 01-03-2024 |
$16.42 | $16.41 | $16.42 | $16.44 | $16.41 | 76,192 | 01-02-2024 |
$16.45 | $16.42 | $16.45 | $16.45 | $16.41 | 67,322 | 01-01-2024 |
$16.45 | $16.42 | $16.45 | $16.45 | $16.41 | 67,322 | 12-29-2023 |
$16.42 | $16.425 | $16.42 | $16.4401 | $16.41 | 61,877 | 12-28-2023 |
$16.43 | $16.45 | $16.43 | $16.45 | $16.405 | 60,591 | 12-27-2023 |
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with th...